Derailing the aspartate pathway of Mycobacterium tuberculosis to eradicate persistent infection

Erik J. Hasenoehrl, Dannah Rae Sajorda, Linda Berney-Meyer, Samantha Johnson, Jo Ann M. Tufariello, Tobias Fuhrer, Gregory M. Cook, William R. Jacobs, Michael Berney

Research output: Contribution to journalArticle

Abstract

A major constraint for developing new anti-tuberculosis drugs is the limited number of validated targets that allow eradication of persistent infections. Here, we uncover a vulnerable component of Mycobacterium tuberculosis (Mtb) persistence metabolism, the aspartate pathway. Rapid death of threonine and homoserine auxotrophs points to a distinct susceptibility of Mtb to inhibition of this pathway. Combinatorial metabolomic and transcriptomic analysis reveals that inability to produce threonine leads to deregulation of aspartate kinase, causing flux imbalance and lysine and DAP accumulation. Mtb's adaptive response to this metabolic stress involves a relief valve-like mechanism combining lysine export and catabolism via aminoadipate. We present evidence that inhibition of the aspartate pathway at different branch-point enzymes leads to clearance of chronic infections. Together these findings demonstrate that the aspartate pathway in Mtb relies on a combination of metabolic control mechanisms, is required for persistence, and represents a target space for anti-tuberculosis drug development.

Original languageEnglish (US)
Number of pages1
JournalNature communications
Volume10
Issue number1
DOIs
StatePublished - Sep 16 2019

Fingerprint

aspartates
tuberculosis
infectious diseases
Mycobacterium tuberculosis
Aspartic Acid
Threonine
Lysine
Tuberculosis
Aspartate Kinase
Infection
Homoserine
lysine
Pressure relief valves
Physiological Stress
Metabolomics
Deregulation
Metabolism
drugs
relief valves
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Chemistry(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Physics and Astronomy(all)

Cite this

Hasenoehrl, E. J., Rae Sajorda, D., Berney-Meyer, L., Johnson, S., Tufariello, J. A. M., Fuhrer, T., ... Berney, M. (2019). Derailing the aspartate pathway of Mycobacterium tuberculosis to eradicate persistent infection. Nature communications, 10(1). https://doi.org/10.1038/s41467-019-12224-3

Derailing the aspartate pathway of Mycobacterium tuberculosis to eradicate persistent infection. / Hasenoehrl, Erik J.; Rae Sajorda, Dannah; Berney-Meyer, Linda; Johnson, Samantha; Tufariello, Jo Ann M.; Fuhrer, Tobias; Cook, Gregory M.; Jacobs, William R.; Berney, Michael.

In: Nature communications, Vol. 10, No. 1, 16.09.2019.

Research output: Contribution to journalArticle

Hasenoehrl, EJ, Rae Sajorda, D, Berney-Meyer, L, Johnson, S, Tufariello, JAM, Fuhrer, T, Cook, GM, Jacobs, WR & Berney, M 2019, 'Derailing the aspartate pathway of Mycobacterium tuberculosis to eradicate persistent infection', Nature communications, vol. 10, no. 1. https://doi.org/10.1038/s41467-019-12224-3
Hasenoehrl EJ, Rae Sajorda D, Berney-Meyer L, Johnson S, Tufariello JAM, Fuhrer T et al. Derailing the aspartate pathway of Mycobacterium tuberculosis to eradicate persistent infection. Nature communications. 2019 Sep 16;10(1). https://doi.org/10.1038/s41467-019-12224-3
Hasenoehrl, Erik J. ; Rae Sajorda, Dannah ; Berney-Meyer, Linda ; Johnson, Samantha ; Tufariello, Jo Ann M. ; Fuhrer, Tobias ; Cook, Gregory M. ; Jacobs, William R. ; Berney, Michael. / Derailing the aspartate pathway of Mycobacterium tuberculosis to eradicate persistent infection. In: Nature communications. 2019 ; Vol. 10, No. 1.
@article{d932658fa4e84a7cb820bc0af008cd61,
title = "Derailing the aspartate pathway of Mycobacterium tuberculosis to eradicate persistent infection",
abstract = "A major constraint for developing new anti-tuberculosis drugs is the limited number of validated targets that allow eradication of persistent infections. Here, we uncover a vulnerable component of Mycobacterium tuberculosis (Mtb) persistence metabolism, the aspartate pathway. Rapid death of threonine and homoserine auxotrophs points to a distinct susceptibility of Mtb to inhibition of this pathway. Combinatorial metabolomic and transcriptomic analysis reveals that inability to produce threonine leads to deregulation of aspartate kinase, causing flux imbalance and lysine and DAP accumulation. Mtb's adaptive response to this metabolic stress involves a relief valve-like mechanism combining lysine export and catabolism via aminoadipate. We present evidence that inhibition of the aspartate pathway at different branch-point enzymes leads to clearance of chronic infections. Together these findings demonstrate that the aspartate pathway in Mtb relies on a combination of metabolic control mechanisms, is required for persistence, and represents a target space for anti-tuberculosis drug development.",
author = "Hasenoehrl, {Erik J.} and {Rae Sajorda}, Dannah and Linda Berney-Meyer and Samantha Johnson and Tufariello, {Jo Ann M.} and Tobias Fuhrer and Cook, {Gregory M.} and Jacobs, {William R.} and Michael Berney",
year = "2019",
month = "9",
day = "16",
doi = "10.1038/s41467-019-12224-3",
language = "English (US)",
volume = "10",
journal = "Nature Communications",
issn = "2041-1723",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Derailing the aspartate pathway of Mycobacterium tuberculosis to eradicate persistent infection

AU - Hasenoehrl, Erik J.

AU - Rae Sajorda, Dannah

AU - Berney-Meyer, Linda

AU - Johnson, Samantha

AU - Tufariello, Jo Ann M.

AU - Fuhrer, Tobias

AU - Cook, Gregory M.

AU - Jacobs, William R.

AU - Berney, Michael

PY - 2019/9/16

Y1 - 2019/9/16

N2 - A major constraint for developing new anti-tuberculosis drugs is the limited number of validated targets that allow eradication of persistent infections. Here, we uncover a vulnerable component of Mycobacterium tuberculosis (Mtb) persistence metabolism, the aspartate pathway. Rapid death of threonine and homoserine auxotrophs points to a distinct susceptibility of Mtb to inhibition of this pathway. Combinatorial metabolomic and transcriptomic analysis reveals that inability to produce threonine leads to deregulation of aspartate kinase, causing flux imbalance and lysine and DAP accumulation. Mtb's adaptive response to this metabolic stress involves a relief valve-like mechanism combining lysine export and catabolism via aminoadipate. We present evidence that inhibition of the aspartate pathway at different branch-point enzymes leads to clearance of chronic infections. Together these findings demonstrate that the aspartate pathway in Mtb relies on a combination of metabolic control mechanisms, is required for persistence, and represents a target space for anti-tuberculosis drug development.

AB - A major constraint for developing new anti-tuberculosis drugs is the limited number of validated targets that allow eradication of persistent infections. Here, we uncover a vulnerable component of Mycobacterium tuberculosis (Mtb) persistence metabolism, the aspartate pathway. Rapid death of threonine and homoserine auxotrophs points to a distinct susceptibility of Mtb to inhibition of this pathway. Combinatorial metabolomic and transcriptomic analysis reveals that inability to produce threonine leads to deregulation of aspartate kinase, causing flux imbalance and lysine and DAP accumulation. Mtb's adaptive response to this metabolic stress involves a relief valve-like mechanism combining lysine export and catabolism via aminoadipate. We present evidence that inhibition of the aspartate pathway at different branch-point enzymes leads to clearance of chronic infections. Together these findings demonstrate that the aspartate pathway in Mtb relies on a combination of metabolic control mechanisms, is required for persistence, and represents a target space for anti-tuberculosis drug development.

UR - http://www.scopus.com/inward/record.url?scp=85072272776&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85072272776&partnerID=8YFLogxK

U2 - 10.1038/s41467-019-12224-3

DO - 10.1038/s41467-019-12224-3

M3 - Article

VL - 10

JO - Nature Communications

JF - Nature Communications

SN - 2041-1723

IS - 1

ER -